Skip to main content

Table 4 Symptoms, classification, and risk factors of ESLD patients at presentation

From: Ambulatory end-stage liver disease in Ghana; patient profile and utility of alpha fetoprotein and aspartate aminotransferase: platelet ratio index

 

HCC

n/Na (%)

Cirrhosis

n/Na (%)

p value

Abdominal pain or discomfort

110/129 (85.2)

122/204 (59.8)

< 0.001

Jaundice

38/128 (29.7)

59/204 (28.9)

0.88

Weight loss

115/128 (89.8)

172/204 (84.3)

0.15

Anorexia

67/128 (52.3)

64/205 (31.2)

< 0.001

Fever

61/126 (48.4)

85/203 (41.9)

0.25

Ascites (clinically determined)

 None

60/133 (45.1)

57/203 (28.1)

0.001

 Mild

24/133 (18.0)

60/203 (29.6)

0.02

 Moderate–Severe

49/133 (36.8)

86/203 (42.4)

0.3

Hepatic encephalopathy

 None

118/129 (91.5)

194/202 (96.0)

0.08

 Grade 1–2

11/129 (8.5)

8/202 (4.0)

0.08

Child–Pugh Class

 A

12/32 (37.5)

17/83 (20.5)

0.01

 B

15/32 (46.8)

35/83 (42.2)

0.9

 C

5/32 (15.6%)

31/83 (37.3)

0.01

Risk factors

 HBV

98 (69.5)

102 (47.2)

< 0.001

 HCV

9 (6.4)

8 (3.7)

0.3

 Alcohol

15 (10.6)

63 (29.2)

< 0.001

 Autoimmune

1 (0.7)

4 (1.9)

0.3

 NAFLD

0 (0)

3 (1.4)

0.1

 Unknownb

22 (15.6)

40 (18.5)

0.4

  1. aThe total number of patients was 141 HCC, 216 liver cirrhosis and 218 chronic HBV, however not all questions were answered by all participants
  2. bUnknown after testing for viral hepatitis and without history suggestive of other causes